Shockwave Medical

Executive Summary

Shockwave Medical is a privately held medical device company pioneering Intravascular Lithotripsy (IVL) technology to treat calcified cardiovascular disease. IVL leverages sonic pressure waves to fracture calcium deposits in arterial walls, offering a safe, effective, and intuitive solution for both coronary and peripheral vascular applications. The technology addresses a significant unmet need, as calcified lesions are historically difficult to treat with conventional balloons or stents, often leading to suboptimal outcomes or complications. Shockwave's platform has been adopted by leading interventional cardiologists and vascular surgeons, positioning the company as a key innovator in the cardiovascular space. The company's focus on underserved high-risk patient populations has driven strong clinical adoption and growing revenue. Shockwave has secured FDA approvals for multiple IVL catheters across coronary and peripheral indications, and continues to expand its product pipeline. With a robust intellectual property portfolio and a direct sales force in the U.S., the company is well-positioned to capture a significant share of the growing calcified lesion treatment market. Looking ahead, Shockwave Medical is expected to benefit from continued clinical evidence generation, potential label expansions, and strategic partnerships that could further accelerate its commercial trajectory.

Upcoming Catalysts (preview)

• Q2 2026FDA approval for next-generation coronary IVL catheter85% success
• Q3 2026Pivotal trial results for IVL in peripheral artery disease75% success
• Q4 2026Strategic partnership or acquisition interest from major cardiovascular company60% success